|
Item
|
Value
|
Percentage
|
|---|
|
Age (median)
|
33 (15–74) years
|
|
Gender
|
Male: female
|
37%: 63%
|
|
HB level
|
≥ 10.5 g/dl
|
64%
|
|
< 10.5 g/dl
|
36%
|
|
WBC
|
≥ 15 × 109/l
|
15%
|
|
< 15 × 109/l
|
85%
|
|
Serum albumin
|
<4 g/dl
|
35%
|
|
≥4 g/dl
|
65%
|
|
HCV antibodies
|
Positive
|
14%
|
|
Negative
|
86%
|
|
Performance status
|
<2
|
95%
|
|
≥2
|
5%
|
|
B symptoms
|
Absent
|
46%
|
|
Present
|
54%
|
|
Bulky disease
|
No
|
89%
|
|
Yes
|
11%
|
|
Histopathology subtype
|
Mixed cellularity
|
46%
|
|
Nodular sclerosis
|
42%
|
|
Lymphocyte rich
|
12%
|
|
Extra nodal disease
|
No
|
73%
|
|
Yes
|
27%
|
|
Spleen involvement
|
No
|
78%
|
|
Yes
|
22%
|
|
Bone marrow involvement
|
No
|
96%
|
|
Yes
|
4%
|
|
Ann Arbor stage
|
I
|
1%
|
|
II
|
27%
|
|
III
|
42%
|
|
IV
|
30%
|
|
Stage
|
Limited
|
21%
|
|
Advanced
|
79%
|
|
IPS
|
< 3
|
60%
|
|
≥ 3
|
40%
|
|
CD 68
|
I
|
41%
|
|
II
|
41%
|
|
III
|
18%
|
|
CD 163
|
I
|
37%
|
|
II
|
40%
|
|
III
|
23%
|
|
Response
|
CR
|
61%
|
|
PR
|
12%
|
|
PD
|
7%
|
|
SD
|
20%
|
|
Relapse after CR
|
Yes:no
|
20%:41%
|
|
Status
|
Alive:dead
|
82%:18%
|
- HB hemoglobin, WBC white blood cell count, HCV, hepatitis C virus, CR complete response, PR partial Response, PD progressive disease, SD stationary disease, IPS International Prognostic score
